Trials / Recruiting
RecruitingNCT03746535
Cardiovascular Disease Risk in Women With Endometriosis
Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Yale University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Detailed description
Our scientific premise is that in women with endometriosis, elevated cardiovascular disease risk is the result of endothelial dysfunction and chronic systemic inflammation through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elagolix | Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days. |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-31
- First posted
- 2018-11-19
- Last updated
- 2025-05-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03746535. Inclusion in this directory is not an endorsement.